P809 VARIETY BEACH: Real-world treatment patterns for vedolizumab intravenous and subcutaneous maintenance dosing observed over 1 year in studies from Belgium, Austria and Switzerland

Abstract

Background: Real-world data on VDZ treatment patterns in pa-tients (pts) with inflammatory bowel disease (IBD) comparing VDZ IV or SC maintenance are still scarce. Method(s): Three observational studies enrolled pts in Belgium, Austria and Switzerland. Adults initiating VDZ IV induction or continuing VDZ IV maintenance with the option to switch to SC, were eligible. The primary endpoint was VDZ treatment persis-tence at 1 year. Administration route, dosing frequency, rea-sons for regimen change and safety endpoints were also as-sessed. Result(s): Of 377 pts enrolled, 373 (UC = 218, CD = 155) were included. At enrolment, 287 (77%) (UC = 159, CD = 128) re-ceived VDZ IV maintenance for median 2.8 (0-12.6) years and 86 (23%) (UC = 59, CD = 27) started VDZ induction. Pts enrolled on VDZ IV maintenance had a persistence rate at 1 year of 79% (227/287) and of these 39% (88/227) switched from VDZ IV maintenance to SC during the study. Patients enrolled on VDZ induction, showed a VDZ treatment persistence of 66% (57/86) at 1 year and of these 56% (32/57) switched to VDZ SC during the study (Figure 1). Overall, the most common reasons for ad-ministration route changes were pt decision 98/161 (61%), end of induction with planned switch (10%) and disease adequately controlled (6%). Adverse events (AEs) occurred in 48 pts (13%) and serious AEs in 6 pts (2%). Conclusion(s): Real-world data from prospective observational studies in Belgium, Austria and Switzerland reported high per-sistence of VDZ IV and SC maintenance treatment over 1 year. Decisions on route of administration change were most fre-quently driven by patients. Safety results were consistent with the known safety profile of VDZ.